Descovy
E409695
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Descovy canonical | 1 |
| emtricitabine | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050928 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Descovy Context triple: [Gilead Sciences, product, Descovy]
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Descovy Target entity description: Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
HIV medication
ⓘ
antiretroviral medication ⓘ combination drug ⓘ pharmaceutical drug ⓘ |
| ATCCode | J05AR17 ⓘ |
| benefitComparedToTDFRegimens |
less impact on bone mineral density
ⓘ
less impact on renal function ⓘ |
| blackBoxWarning |
post-treatment acute exacerbation of hepatitis B
ⓘ
risk of drug resistance with use as monotherapy for HIV-1 ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ headache ⓘ nausea ⓘ |
| containsComponentBrand |
emtricitabine
ⓘ
tenofovir alafenamide ⓘ |
| containsSubstance |
emtricitabine 120 mg (in pediatric tablet strength)
ⓘ
emtricitabine 200 mg (in one tablet strength) ⓘ tenofovir alafenamide 15 mg (in pediatric tablet strength) ⓘ tenofovir alafenamide 25 mg (in one tablet strength) ⓘ |
| contraindication | severe renal impairment (per label thresholds) ⓘ |
| countryOfApproval |
United States of America
ⓘ
surface form:
United States
|
| developer |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| dosageForm | film-coated tablet ⓘ |
| drugClass |
nucleoside reverse transcriptase inhibitor
ⓘ
nucleotide reverse transcriptase inhibitor ⓘ |
| formulation | oral tablet ⓘ |
| hasActiveIngredient |
emtricitabine
ⓘ
tenofovir alafenamide ⓘ |
| indication |
PrEP for HIV-1
ⓘ
pre-exposure prophylaxis of HIV-1 infection ⓘ treatment of HIV-1 infection ⓘ |
| indicationLimitation | not indicated for PrEP in individuals at risk from receptive vaginal sex (per U.S. label as of 2024) ⓘ |
| indicationPopulation |
adolescents at risk of HIV-1 infection
ⓘ
adolescents with HIV-1 infection ⓘ adults at risk of HIV-1 infection ⓘ adults with HIV-1 infection ⓘ |
| legalStatus | prescription-only ⓘ |
| manufacturer |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| mechanismOfAction |
inhibition of HIV-1 reverse transcriptase
ⓘ
termination of viral DNA chain elongation ⓘ |
| onceDaily | true ⓘ |
| pregnancyCategory | consult label and clinician for use in pregnancy ⓘ |
| regulatoryAgency |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| routeOfAdministration | oral ⓘ |
| therapeuticArea |
HIV prevention
ⓘ
HIV treatment ⓘ infectious disease ⓘ |
| usedWith | other antiretroviral agents for HIV-1 treatment ⓘ |
| warning |
risk of acute exacerbation of hepatitis B after discontinuation
ⓘ
risk of lactic acidosis ⓘ risk of severe hepatomegaly with steatosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Descovy Description of subject: Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Gilead Sciences
this entity surface form:
emtricitabine